Ambrox-Denk 60 is a supportive treatment commonly used to help with respiratory conditions where the primary symptomatic burden is caused by thick, tenacious mucus that is difficult to expel. It provides targeted relief across acute and chronic scenarios where mucus clearance has become affected.

Symptom Management and Therapeutic Scope

This medication is applied across therapeutic domains involving certain distressing symptoms of the respiratory tract. It is used in the context of acute and chronic bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport. The core therapeutic benefit is to ease the clearance of phlegm, which helps address the issue of impaired mucus transport and assists patients with maintaining stability during symptom fluctuations. The drug is relevant for managing symptoms that interfere with daily comfort, such as difficult expectoration, chest congestion, and viscid mucus accumulation.

This medication is commonly used across conditions presenting with acute episodes, including chronic bronchitis, acute exacerbations of bronchitis, and tracheobronchitis. It is used in situations involving recurrent or episodic manifestations, often when symptoms intensify and supportive relief is needed. By supporting the easier clearance of phlegm, the medication contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

---

Quick Fact: Relief for Difficult Expectorations

Scope	Description
Main Use	Addressing symptomatic burdens from thick, viscid respiratory mucus.
Relieves	Ineffective productive cough, chest congestion, impaired phlegm clearance.
Context	Acute and chronic bronchopulmonary diseases.
Benefit	Supports easier, more effective expulsion of secretions.

Regulatory References

1. Hong Kong Department of Health notice

Who can and cannot use Ambrox-Denk 60?

This section outlines the official population eligibility and non-eligibility rules for Ambroxol hydrochloride, the active ingredient in Ambrox-Denk 60, based on governmental regulatory documents.

---

Absolute Non-Eligibility (Contraindications)

Classification	Population/Condition
Prohibited	Patients with known hypersensitivity to Ambroxol or excipients.
Prohibited	Children under 2 years of age.
Prohibited	Patients with rare hereditary problems of fructose intolerance (due to the effervescent tablet excipients).

---

Conditional or Restricted Eligibility

Use of this medicine requires caution or is not recommended in certain populations as stated in the regulatory label:

• Organ Impairment: Caution is required for patients with severe renal impairment or severe hepatic impairment.
• Comorbidities: Caution is necessary for individuals with a history of peptic or duodenal ulcers.
• Airway: Caution is also advised for patients with compromised airway motility, such as primary ciliary dyskinesia.

---

Physiological Status

• Pregnancy: Use is not recommended during the first trimester (first 28 weeks).
• Lactation: Use is not recommended for nursing mothers, as the substance is excreted into breast milk.

Interactions with other medicines and products

The official interaction profile for Ambrox-Denk 60 is defined by a primary restriction involving a pharmacodynamic conflict and a documented pharmacokinetic exposure modification. Regulatory information for the active ingredient, ambroxol hydrochloride, indicates that no clinically relevant unfavorable interactions with most other medicines have been reported.

Officially Documented Interaction Patterns

Interaction Type	Interacting Substance	Regulatory Restriction/Outcome
Pharmacodynamic	Cough Suppressants (Antitussives)	Co-administration is not recommended due to the risk of serious obstruction of the airways resulting from suppressed cough reflex and mucus accumulation.
Pharmacokinetic	Antibiotics (Amoxicillin, Cefuroxime, Erythromycin, Doxycycline)	Co-administration leads to an increase in the concentration of these antibiotics specifically in bronchopulmonary secretions.

Population-Specific Interaction Considerations

Interaction relevance is officially noted in patient populations with impaired clearance. In cases of severe renal impairment, the accumulation of hepatic metabolites of ambroxol is expected. Additionally, a reduction in ambroxol clearance may be observed in patients with severe hepatic impairment.

This interaction structure is based strictly on the classification and data presented in governmental product characteristics summaries, which define the product's use-with-caution constraints and pharmacokinetic effects.

Pharmacodynamics: Mechanism of Action

Ambroxol, the active component, operates through three complementary pharmacodynamic mechanisms within the respiratory system to modulate the physical properties of secretions.

Mucus Rheology and Breakdown

The molecule functions as a mucolytic, chemically engaging the acidic mucopolysaccharide fibers and DNA present in respiratory mucus. This direct interaction causes the depolymerization of these complex structures. The resulting chemical action reduces the intrinsic viscosity and stickiness of the secretions, causing a physical alteration that facilitates the movement of the mucus layer.

Airway Fluid Secretion and Transport

Ambroxol acts as a secretion stimulator, primarily targeting Type II pneumocytes and serous gland cells in the bronchial tissue. This stimulus increases the synthesis and release of pulmonary surfactant, which reduces the surface tension of the mucus. It also promotes the flow of low-viscosity serous fluid. This dual action enhances the lubrication and flow, resulting in an increased function of the mucociliary transport system.

Local Cellular Modulation

Ambroxol exhibits localized effects by temporarily inhibiting voltage-gated Na^+ channels on sensory nerve endings in the mucosa. This action leads to a reduction in the excitability of local sensory nerve fibers. Furthermore, the molecule demonstrates antioxidant properties, neutralizing Reactive Oxygen Species (ROS), which results in a reduction of excessive cellular oxidative stress on the bronchial tissue.

How to Use Ambrox-Denk 60

This section outlines the administration and dosing for Ambroxol hydrochloride 60 mg effervescent tablets.

---

Administration and Preparation

Ambrox-Denk 60 is for oral administration. Due to its effervescent tablet form, the medicine must be fully dissolved in a glass of water before ingestion. The dose is typically taken after meals (postprandially) and ample liquid intake should be maintained throughout the day.

Standard Adult Dosing Regimens

Dosing follows a two-part schedule, often beginning with a higher dose for an initial period to establish effective levels:

Regimen	Dose	Frequency	Total Daily Dose
Initial Treatment (First 2–3 days)	30 mg	Three times daily (TID)	90 mg
Maintenance Treatment (Subsequent days)	30 mg	Twice daily (BID)	60 mg

Alternatively, a dose of 60 mg (one effervescent tablet) may be taken twice daily for situations requiring increased efficacy, totaling 120 mg per day.

---

Specific Use Conditions

Duration: For acute conditions, the medication is intended for short-term use. If symptoms worsen or do not improve after 5 days of treatment, medical guidance should be sought.

Population-Specific Adjustments: Use requires caution in patients with severe renal or hepatic impairment. A lower dose or extended intervals between doses may be necessary in cases of severe renal insufficiency to prevent the accumulation of metabolites. Use is contraindicated in children under 2 years of age.

Research evidence / Overview of studies for Ambrox-Denk 60

The research base for Ambroxol hydrochloride, the active ingredient in Ambrox-Denk 60, has been established through several types of clinical trials and systematic reviews. The available evidence describes how the compound was studied in specific respiratory conditions, with research focusing on changes in mucus-related symptoms and long-term condition stability.

---

Evidence for Use in Acute Respiratory Conditions

Ambroxol was evaluated in short-term Randomized Controlled Trials (RCTs) conducted during periods of increased symptom activity, such as acute bronchitis. These trials primarily examined outcomes related to physical discomfort, monitoring changes in patient-reported scores for cough severity, and difficulty of clearing phlegm. Research also monitored objective measures of mucus. Follow-up durations were limited, focusing only on the span of the acute episode, meaning data are still emerging regarding whether this pattern of change translates into long-term differences.

---

Evidence for Use in Chronic Bronchopulmonary Conditions

The evidence for chronic conditions, such as Chronic Obstructive Pulmonary Disease (COPD), includes longer-duration studies. This research explored the compound’s role in patients managing symptoms over several months, focusing on the frequency of acute exacerbations and stability. Research examined exacerbation frequency in some long-term cohorts, but historical RCTs in certain groups did not identify an advantage on every outcome measure, leading to some mixed findings across the body of evidence. Comparative evidence is lacking regarding how these patterns compare to a full range of standard treatment options.

---

Long-Term Research and Durability of Study Findings

The research base includes trials with extended observation periods, primarily involving conditions where symptoms may vary in intensity. The long-term trials focused on assessing whether patterns of exacerbation frequency persisted over observation intervals of six to twelve months. Research provides context on longer periods of use, but long-term effects are not fully established regarding high-level outcomes, such as mortality or overall reduction in disease severity.

---

Evidence in Specific Patient Cohorts

Research has also explored the use of Ambroxol in populations including children and elderly adults. A key limitation noted in regulatory reviews is that data for certain groups remain insufficient. Specifically, some regulatory assessments have concluded that evidence quality varies across studies, particularly regarding the secretolytic effects for children below the age of six years; this means that subgroup findings are uncertain in this young population.

Key Studies & References

1. Mucokinetics and bronchial secretion: assessment of the effects of ambroxol (Sputum viscosity study)
2. WHO ATC Classification: R05CB06 (Ambroxol)

Common questions about Ambrox-Denk 60 (FAQ)

---

Q: How quickly does Ambrox-Denk 60 usually start to work?

Official pharmacological data indicates that the active ingredient generally reaches its highest concentration in the blood plasma, known as the peak, approximately 1 to 2 hours after the dose is taken orally. This measurement is used to characterize how quickly the active ingredient is absorbed into the system.

---

Q: How long can I expect the effects of Ambrox-Denk 60 to last after taking it?

Pharmacokinetic studies indicate the terminal elimination half-life of the active ingredient in the plasma ranges between approximately 7 and 12 hours after repeated doses. This pharmacokinetic measure helps characterize the time it takes for the substance to be eliminated from the body.

---

Q: What foods or drinks should people be aware of while taking this medication?

No specific interaction warnings with general food products or non-alcoholic drinks are listed in the regulatory documents. However, official administration guidelines exist regarding taking the dose relative to meals.

---

Q: What should I do if I miss a dose of Ambrox-Denk 60?

Official product information provides general guidance for managing a missed dose. These instructions typically advise against taking a double dose to compensate for the one that was missed.

---

Q: What is the difference between Ambrox-Denk 60 and other over-the-counter cough medicines?

Ambrox-Denk 60 contains ambroxol, which is classified as a mucolytic agent. This means it functions to help thin the mucus. Many other common cough medicines are classified as antitussives (cough suppressants), which work differently by suppressing the urge to cough.

---

Q: Does Ambrox-Denk 60 affect driving or operating machinery?

Official regulatory summaries indicate that, based on the known safety profile, the medicine is generally considered to have no or negligible influence on the ability to drive or use machines.

---

Q: Is it safe to take Ambrox-Denk 60 while also taking pain relievers?

Regulatory information indicates that no clinically relevant unfavorable interactions are currently known with other general medications, including pain relievers, or with alcohol. However, official cautions advise against taking this medicine simultaneously with cough suppressants (antitussives).

---

Q: What does 'contraindication' mean in the context of Ambrox-Denk 60?

A contraindication refers to a condition or factor that officially serves as a reason to withhold a medical treatment. When a condition is listed in the regulatory documents, it indicates that the use of the medicine is considered inappropriate due to the potential for harm or adverse effects.

---

Q: Is Ambrox-Denk 60 known to cause drowsiness?

Drowsiness is not listed as a common or uncommon adverse reaction in official safety summaries. Regulatory texts further indicate the medicine has a negligible influence on the ability to drive.

---

Q: What are the signs that Ambrox-Denk 60 is working?

The product’s mechanism of action is designed to reduce the thickness and viscosity of respiratory secretions. This process helps to facilitate the natural clearing of mucus and expectoration from the airways.

---

Q: What is the official definition of the condition Ambrox-Denk 60 is intended to treat?

According to official regulatory documents, the medicine is indicated for the secretory therapy of acute and chronic broncho-pulmonary diseases. These are conditions that are associated with the abnormal or excessive production of mucus and impaired transport of mucus within the respiratory system.

---

Q: Is Ambrox-Denk 60 safe for individuals who have asthma?

The official product label indicates a required caution for use in individuals who have asthma. This precaution is especially relevant for patients who have a history of serious asthmatic attacks.

---

Q: Does Ambrox-Denk 60 contain sugar or gluten (for dietary concerns)?

Regulatory product information notes that excipients, such as Sorbitol and Lactose, may be present in some formulations. A warning is included regarding a rare hereditary condition known as fructose intolerance. Specific information regarding gluten content may vary or is not always listed in regulatory documents.

---

Q: Can I stop taking Ambrox-Denk 60 suddenly?

Official guidance advises against stopping the use of this medicine abruptly. Regulatory instructions emphasize that discontinuation should occur only when directed or advised by a healthcare professional.

---

Q: Is Ambrox-Denk 60 appropriate for older adults (the elderly)?

Regulatory documents note that caution is required for use in all patients, including older adults, who have severe impairment of the kidneys (renal) or liver (hepatic). Lower dosage or extended intervals may be necessary in these specific conditions.

Official Storage Requirements

Regulatory documents stipulate specific conditions to maintain the stability of Ambrox-Denk 60 (Ambroxol effervescent tablets). The product must be stored at a temperature that does not exceed 30 C to preserve its three-year shelf-life. Due to the moisture-sensitive nature of the tablets, the container must be kept tightly closed immediately after use and the product must be protected from moisture throughout storage, typically by remaining in the original tube with its desiccant stopper. The medicine must always be kept out of the sight and reach of children.

Disposal Instructions

When discarding unused or expired Ambrox-Denk 60, it should not be disposed of in household wastewater or drains. Official instructions recommend consulting a pharmacy or medical institution for guidance or utilizing an authorized drug take-back program to ensure the proper disposal of pharmaceutical waste.